Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chronic obstructive pulmonary disease (COPD ) characterized by an eosinophilic phenotype.
The purpose of the LTS 18211 study is to characterize the long-term safety and efficacy of lunsekimig in adults with COPD who completed studies EFC18243 or EFC18244 in the main study, and to assess the impact of inhaled corticosteroids (ICS ) withdrawal in the ICS withdrawal sub-study.
The study duration will be up to 100 weeks, including the following components:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants who completed the treatment period of EFC18243 or EFC18244 studies, including EOI visit
Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:
Female participants: not pregnant or breastfeeding, and one of the following conditions applies:
Male participants: No sperm donation or cryopreserving sperm
ICS-withdrawal sub-study only:
Exclusion criteria
The exclusion criteria are identical for LTS18211 and ICS withdrawal sub-study:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
1,508 participants in 3 patient groups
Loading...
Central trial contact
Trial Transparency email recommended (Toll free for US & Canada)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal